187 related articles for article (PubMed ID: 31646465)
1. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
[TBL] [Abstract][Full Text] [Related]
2. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
3. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
[TBL] [Abstract][Full Text] [Related]
4. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
[TBL] [Abstract][Full Text] [Related]
5. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
Kumada H; Watanabe T; Suzuki F; Ikeda K; Sato K; Toyoda H; Atsukawa M; Ido A; Takaki A; Enomoto N; Kato K; Alves K; Burroughs M; Redman R; Pugatch D; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Chayama K
J Gastroenterol; 2018 Apr; 53(4):566-575. PubMed ID: 29052790
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.
Lampertico P; Carrión JA; Curry M; Turnes J; Cornberg M; Negro F; Brown A; Persico M; Wick N; Porcalla A; Pangerl A; Crown E; Larsen L; Yu Y; Wedemeyer H
J Hepatol; 2020 Jun; 72(6):1112-1121. PubMed ID: 32061651
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
Asselah T; Lee SS; Yao BB; Nguyen T; Wong F; Mahomed A; Lim SG; Abergel A; Sasadeusz J; Gane E; Zadeikis N; Schnell G; Zhang Z; Porcalla A; Mensa FJ; Nguyen K
Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):45-51. PubMed ID: 30393106
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
Back D; Belperio P; Bondin M; Negro F; Talal AH; Park C; Zhang Z; Pinsky B; Crown E; Mensa FJ; Marra F
J Viral Hepat; 2019 Aug; 26(8):951-960. PubMed ID: 30977945
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
[TBL] [Abstract][Full Text] [Related]
12. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
Foster GR; Asselah T; Kopecky-Bromberg S; Lei Y; Asatryan A; Trinh R; Zadeikis N; Mensa FJ
PLoS One; 2019; 14(1):e0208506. PubMed ID: 30601818
[TBL] [Abstract][Full Text] [Related]
14. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
[TBL] [Abstract][Full Text] [Related]
16. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
[TBL] [Abstract][Full Text] [Related]
17. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Wyles D; Poordad F; Wang S; Alric L; Felizarta F; Kwo PY; Maliakkal B; Agarwal K; Hassanein T; Weilert F; Lee SS; Kort J; Lovell SS; Liu R; Lin CW; Pilot-Matias T; Krishnan P; Mensa FJ
Hepatology; 2018 Feb; 67(2):514-523. PubMed ID: 28926120
[TBL] [Abstract][Full Text] [Related]
18. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
